Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2020 1
2024 8
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Pre-Clinical Models for CAR T-Cell Therapy for Glioma.
Vandecandelaere G, Ramapriyan R, Gaffey M, Richardson LG, Steuart SJ, Tazhibi M, Kalaw A, Grewal EP, Sun J, Curry WT, Choi BD. Vandecandelaere G, et al. Among authors: grewal ep. Cells. 2024 Sep 4;13(17):1480. doi: 10.3390/cells13171480. Cells. 2024. PMID: 39273050 Free PMC article. Review.
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
Ramapriyan R, Barker FG 2nd, Richardson LG, Sun J, Vandecandelaere G, Shim JM, De Vlaminck G, Gaffey M, Grewal EP, Tazhibi M, Morshedy K, Aref AR, Batool SM, Guo X, Ijad N, Balaj L, Wakimoto H, Martinez-Lage M, Frigault MJ, Leick MB, Bernstock JD, Bi WL, Carter BS, Chiocca EA, Dietrich J, Gerstner ER, Boland GM, Nahed BV, Plotkin SR, Jenkins RW, Brastianos PK, Curry WT, Maus MV, Choi BD. Ramapriyan R, et al. Among authors: grewal ep. Neuro Oncol. 2025 Jun 28:noaf155. doi: 10.1093/neuonc/noaf155. Online ahead of print. Neuro Oncol. 2025. PMID: 40579924
Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.
Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Carter BS, Cahill DP, Curry WT, Choi BD. Grewal EP, et al. Clin Cancer Res. 2024 Sep 13;30(18):4068-4076. doi: 10.1158/1078-0432.CCR-24-1056. Clin Cancer Res. 2024. PMID: 39042445 Free PMC article.
A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant Glioma.
Tazhibi M, Grewal EP, Ramapriyan R, Richardson LGK, Vandecandelaere G, Kalaw A, Kotlarz P, Steuart SJ, Sun J, Gaffey M, Cahill DP, Miller JJ, Curry WT, Choi BD. Tazhibi M, et al. Among authors: grewal ep. Cancers (Basel). 2025 Jun 27;17(13):2178. doi: 10.3390/cancers17132178. Cancers (Basel). 2025. PMID: 40647477 Free PMC article. Review.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Block MS, Nelson GD, Chen J, Johnson S, Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA, Domingo-Musibay E, Markovic SN, Dimou A, Montane HN, Piltin MA, Price DL, Khariwala SS, Hui JYC, Erskine CL, Strand CA, Zahrieh D, Dong H, Hieken TJ. Block MS, et al. Among authors: grewal ep. J Immunother Cancer. 2025 Apr 15;13(4):e011706. doi: 10.1136/jitc-2025-011706. J Immunother Cancer. 2025. PMID: 40234093 Free PMC article. Clinical Trial.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: grewal ep. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
16 results